Lpx
Finance · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Florastrasse 17, Zürich, Zurich, 8008, S...Phone Number
+41 443829020Website
www.lpx-group.comRevenue
$7.3 MillionIndustry
About Lpx
Is Lpx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Lpx has new funding data
Congratulate Masked Content for being promoted to Masked Content at Lpx
Check if Lpx has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Lpx, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Lpx launches new products
Click to see if Lpx had a recent Job posting/layoffs
Earning: See what the market has to say on Lpx recently announced quarterly report
Check out if Lpx is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Lpx
Find 3 more new buyers
Company Profile Activity
Activity Insights
Lpx is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Lpx is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Lpx.
Lpx Tech Stack
A closer look at the technologies used by Lpx
Lpx News & Media
LAPIX Therapeutics Doses First Patient-In Phase 1b Clinical Trial of LPX-TI641 for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)
CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company focused on developing novel, orally bioavailable immune system restoration therapies for autoimmune diseases based on agonism of TIM (T cell/transmembrane, immunoglobulin, and mucin receptor), today announced the dosing of first subject with its investigational medicine, LPX-TI641, in its Phase 1b clinical trial (NCT06628206). The Phase 1b trial is a randomized, doubLPX AG launches inaugural barometer tracking listed PE universe
LPX AG launches inaugural barometer tracking listed PE universe Submitted 08/06/2022 - 10:01am LPX AG, an alternatives research and index provider, has launched its inaugural Listed Private Equity Barometer, designed to provide detailed data-led insight into the global listed private equity market. Published on a quarterly basis, it presents a snapshot of valuations, performance attribution, allocation, and ESG metrics. The LPX Listed PE Barometer is informed by the LPX Index Series, which serveLouisiana-Pacific (LPX) Q4 Earnings & Sales Top, Margin Falls
Increased selling prices and solid Siding sales aid Louisiana-Pacific's (LPX) fourth-quarter 2021 earnings.
Top Finance Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lpx
LPX AG is a leading research house specializing in alternative asset classes, offering a range of services including indexing, research, and investment advisory. The company provides various index series such as the LPX Listed Private Equity Index Series and the NMX Infrastructure Index Series, catering to clients interested in listed private equit... Read More